Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Perform HIV antibody test prior to initiation of therapy and at least every 3 months and upon diagnosis of any sexually transmitted infections for preexposure prophylaxis (PrEP) in adults and adolescents at high risk.
Monitor ALT,AST, and total bilirubin at baseline and with modification of ARV treatment.
Monitor for several months following therapy discontinuation in patients co-infected with hepatitis B virus and HIV-1.